Swiss National Bank Reduces Holdings in Stryker Corporation $SYK

Posted by Francis Steltz on Jun 12th, 2026

Swiss National Bank cut its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 4.9% in the 4th quarter, HoldingsChannel reports. The fund owned 942,860 shares of the medical technology company’s stock after selling 48,640 shares during the quarter. Swiss National Bank’s holdings in Stryker were worth $331,387,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Godfrey Financial Associates Inc. purchased a new stake in Stryker during the 4th quarter valued at about $26,000. United Financial Planning Group LLC purchased a new stake in Stryker during the 3rd quarter valued at about $27,000. CGC Financial Services LLC purchased a new stake in Stryker during the 4th quarter valued at about $29,000. Strive Asset Management LLC purchased a new stake in Stryker during the 3rd quarter valued at about $30,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in Stryker during the 3rd quarter valued at about $34,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by company insiders.

Stryker Stock Performance

Shares of SYK opened at $305.82 on Friday. The business’s fifty day simple moving average is $316.75 and its two-hundred day simple moving average is $344.20. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The company has a market cap of $117.24 billion, a price-to-earnings ratio of 35.40, a P/E/G ratio of 1.95 and a beta of 0.78.

Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. Stryker’s dividend payout ratio is currently 40.74%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. UBS Group lowered their price target on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research report on Tuesday, March 17th. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Evercore set a $355.00 price target on Stryker in a research report on Friday, May 1st. Finally, Truist Financial reaffirmed a “hold” rating and set a $330.00 price objective (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $395.33.

Read Our Latest Stock Report on Stryker

Stryker Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.